Navigation Links
Symposium to explore role nanoparticles may play in disease
Date:4/2/2008

BETHESDA, Md. (April 2, 2008) Two Mayo Clinic researchers who study the role nanoparticles may play in hardening of the arteries and in the formation of kidney stones, will lead a symposium on how these super-small particles may affect the bodys physiology. The symposium will take place April 8 at the Experimental Biology conference in San Diego.

Nanoparticles are a thousand times smaller than the bacteria, E. coli, but recent advances in microscopy have allowed researchers to watch them interact with cells in the body, said Virginia M. Miller and John C. Lieske of the Mayo Clinic College of Medicine. They will lead the symposium, Using nanotechnology to answer physiological questions.

One of the questions physiologists want to explore is whether nanoparticles can cause diseases such as atherosclerosis, kidney stones, gall stones and periodontal disease. Dr. Lieske is investigating how nano-sized crystals in the kidney can lead to the development of kidney stones. Dr. Miller has been studying the link between atherosclerosis (hardening of the arteries) and nanoparticles which calcify within the arteries.

A fuller audio interview with the researchers is available at www.lifelines.tv.

New technology: promise and peril?

Nanotechnology presents intriguing possibilities and some troubling unknowns. The technology is already applied in commercial products as disparate as flame resistant materials and cosmetics. In addition, the technology holds promise in the development of medications that can target precise areas of the body, such as a tumor.

Because of their size, nanoparticles may more easily gain entry to the body, where the longterm effects are unknown. Dr. Miller has found that some nanoparticles cause inflammation when injected into the blood vessels of animals, an early step in the development of atherosclerosis.

Using the latest in microscopy, Dr. Miller has begun to observe nanoparticles from atherosclerotic tissue. She hopes to determine how these particles gain access to cells and whether the interaction eventually leads to cell activation or death leading to calcification.

Kidneys stones start as tiny calcifications which later become larger and eventually develop into kidney stones. Dr. Lieske hypothesizes that the nanoparticle causes the initial calcification. Once that happens, other processes can take place that results in a kidney stone.

It is not yet known where nanoparticles that are implicated in kidney stones and atherosclerosis originate whether our bodies contain them naturally or we obtain them from the environment.

Miller said research should proceed to determine if nanoparticles are safe over the long term. We may not know some of the consequences until further down the road she said.

Dr. Miller and Dr. Lieske will moderate a program on nanotechnology at Experimental Biology. The speakers are Vitaly Vodyanoy of the University of Auburn; Robert Lee of The Ohio State University; Kevin D. Gillis of the University of Missouri-Columbia and Farooq Shiekh of the Mayo Clinic College of Medicine will present at the symposium.


'/>"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
Source:Eurekalert

Related medicine news :

1. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
2. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
3. Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida
4. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
5. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
6. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
7. AAAS symposium to address significant effects of the male parent in reproductive success
8. Symposium on drug-resistant diseases set for annual AAAS conference
9. Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
10. Experts Offer Global Benefits Strategies at Symposium
11. AST to Address New Concept in Organ Allocation at March 13-16 Winter Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: